- Home
- IAG vs NUVL Comparison
IAG vs NUVL Comparison
Compare IAG & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IAG
- NUVL
- Stock Information
- Founded
- IAG 1990
- NUVL 2017
- Country
- IAG Canada
- NUVL United States
- Employees
- IAG N/A
- NUVL N/A
- Industry
- IAG Precious Metals
- NUVL Biotechnology: Pharmaceutical Preparations
- Sector
- IAG Basic Materials
- NUVL Health Care
- Exchange
- IAG Nasdaq
- NUVL Nasdaq
- Market Cap
- IAG 7.9B
- NUVL 7.1B
- IPO Year
- IAG 1996
- NUVL 2021
- Fundamental
- Price
- IAG $15.52
- NUVL $108.55
- Analyst Decision
- IAG Buy
- NUVL Strong Buy
- Analyst Count
- IAG 4
- NUVL 14
- Target Price
- IAG $15.25
- NUVL $134.29
- AVG Volume (30 Days)
- IAG 10.0M
- NUVL 721.1K
- Earning Date
- IAG 11-04-2025
- NUVL 10-30-2025
- Dividend Yield
- IAG N/A
- NUVL N/A
- EPS Growth
- IAG N/A
- NUVL N/A
- EPS
- IAG 0.59
- NUVL N/A
- Revenue
- IAG $2,234,600,000.00
- NUVL N/A
- Revenue This Year
- IAG $59.71
- NUVL N/A
- Revenue Next Year
- IAG $24.62
- NUVL N/A
- P/E Ratio
- IAG $26.39
- NUVL N/A
- Revenue Growth
- IAG 52.98
- NUVL N/A
- 52 Week Low
- IAG $4.98
- NUVL $55.54
- 52 Week High
- IAG $15.60
- NUVL $112.88
- Technical
- Relative Strength Index (RSI)
- IAG 68.98
- NUVL 63.59
- Support Level
- IAG $12.63
- NUVL $106.02
- Resistance Level
- IAG $14.23
- NUVL $112.11
- Average True Range (ATR)
- IAG 0.80
- NUVL 5.44
- MACD
- IAG 0.21
- NUVL 0.62
- Stochastic Oscillator
- IAG 96.97
- NUVL 81.50
About IAG Iamgold Corporation
Iamgold Corp is a mid-tier gold mining company. The company operating gold mines are divided into geographic segments such as Cote Gold mine - Canada, Burkina Faso - Essakane mine, Westwood mine - Canada. The company's s non-gold mine segments are Exploration and evaluation and development, and Corporate - which includes royalty interests. The company generates the majority of its revenue from the Cote Gold mine segment.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.